SGLT2 Inhibitors and Heart Failure Outcomes
EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization | DAIC
Empagliflozin for heart failure with reduced ejection fraction
SGLT2 Inhibitors in Heart Failure: DAPA-HF & EMPEROR Trials
Dosing for Adults with HF | Jardiance® (empagliflozin) tablets
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine
Revisiting Heart Failure: Guidelines and Beyond
Dosage and administration of SGLT2 inhibitors according to renal... | Download Table
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial - The Lancet Diabetes
Empagliflozin in Heart Failure with a Preserved Ejection Fraction | NEJM
Kidney and heart failure outcomes associated with SGLT2 inhibitor use | Nature Reviews Nephrology
Pharmaceutics | Free Full-Text | The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
Another SGLT2 Inhibitor OK'd for Heart Failure | MedPage Today
EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF | tctmd.com
In the fascinating world of heart failure treatment, SGLT2 inhibitors are up-and-coming! This new FDA indication approval for Jardiance adds to an exciting, evolving treatment landscape. Keep an eye out for the
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure | Journal of the American College of Cardiology
SGLT2 Inhibitors in Heart Failure: DAPA-HF & EMPEROR Trials
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial - ScienceDirect
SGLT2 inhibitors: Sweet (and Salty) Pee — NephJC
Cureus | The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure | Article
Empagliflozin and Heart Failure | Download Scientific Diagram
Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists - ScienceDirect
EMPEROR-Preserved - MyEndoConsult
2021 ESC guideline on Heart Failure: SGLT2 inhibitors finally entering the centre stage and more.
Empagliflozin Effective for Heart Failure, Regardless of Diabetes Status
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF) | Trials | Full Text
